Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2012/04/002591
CTRI/2012/04/002591
Completed
Phase 3

A multicentric open clinical trial to ascertain the role of homoeopathic therapy in vitiligo

Central Council for Research in Homoeopathy New Delhi0 sites500 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- Vitiligo

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: null- Vitiligo
Sponsor
Central Council for Research in Homoeopathy New Delhi
Enrollment
500
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Central Council for Research in Homoeopathy New Delhi

Eligibility Criteria

Inclusion Criteria

  • •All the cases presenting with Vitiligo without any systemic disorder, residing with in approachable distance from the centre.

Exclusion Criteria

  • •Cases suffering from associated diseases:
  • •Severe systemic disease (such as Diabetes mellitus/ Hypertension, etc.)
  • •Pernicious Anaemia
  • •Alopecia Areata
  • •Lichen planus
  • •Downâ??s Syndrome
  • •Hypo/hyperthyroidism
  • •Addisons Disease
  • •Graves Disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
An open multicenter clinical trial to evaluate the safety, tolerability and efficacy of Deferasirox (ICL670) in patients affected by Myelodysplastic syndrome and transfusional chronic hemosiderosis. - GIMEMA MDS 0306ow and intermediate I risk (IPSS score) Myelodysplastic syndrome and transfusion-induced hemosiderosis.MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndrome
EUCTR2006-006147-31-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
Active, not recruiting
Not Applicable
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.partial seizures with or without secondary generalizationMedDRA version: 6.0Level: LLTClassification code 10034089
EUCTR2004-002322-22-DESCHWARZ BIOSCIENCES Inc.160
Active, not recruiting
Phase 1
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalizatio
EUCTR2004-002322-22-CZSCHWARZ BIOSCIENCES, Inc.160
Active, not recruiting
Not Applicable
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.
EUCTR2004-002322-22-SESCHWARZ BIOSCIENCES Inc.160
Active, not recruiting
Not Applicable
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.
EUCTR2004-002322-22-LTSCHWARZ BIOSCIENCES Inc.100